Under the auspices of the National Academy of Sciences (NAS), CSTL and the Board on Life Sciences (BLS) are organizing, in conjunction with the National Academy of Engineering (NAE), Royal Society (RS), Royal Academy of Engineering (RAE), Chinese Academy of Sciences (CAS) and Chinese Academy of Engineering (CAE), three symposia on synthetic biology in 2011-2012. The symposia build on a successful 2009 collaboration between the Royal Society, NAS/NAE, and the Organization for Economic Cooperation and Development (OECD) when these organizations partnered to sponsor an international symposium in Washington, D.C. entitled, Opportunities and Challenges in the Emerging Field of Synthetic Biology (http://sites.nationalacademies.org/PGA/stl/PGA_050738). Following from that meeting, the NAS/NAE and the RS reached an agreement with the RAE and the CAS and CAE to hold three symposia – one in the U.K., one in China, and one in the U.S. – during 2011-2012.
The first symposium, in the U.K., will provide an overview of synthetic biology and developments in the past 5 years; an estimate of what might be achieved in the next 5, 10, and 25 year periods; the requirements and resources necessary for realizing value creation from synthetic biology; and the necessary conditions for an enabling environment. The focus of the symposium in China will be on scientific and technical challenges that must be met to enable further development of the field. The U.S. symposium will focus on next-generation tools, platforms, and infrastructure necessary for continued progress in synthetic biology, and the associated policy implications.
An individually-authored summary of the three symposia will be published as an NRC report.
June 12-13, 2012
Washington, DC
Draft Agenda
Register to Attend
October 12-14, 2011
Shanghai, China
Agenda
April 13-14, 2011
London, England
Agenda
Reports
An individually-authored summary of the three symposia will be published as an NRC report.
MEMBERSHIP
Drew Endy (Chair)
Assistant Professor, Bioengineering
Stanford University
President
The BioBricks Foundation
Michael Elowitz
Howard Hughes Medical Institute Investigator and Associate Professor of Biology, Bioengineering, and Applied Physics
California Institute of Technology
Richard Johnson
CEO
Global Helix LLC
Counsel and Senior Partner (Ret.)
Arnold & Porter, LLP
Wendell Lim
Professor of Cellular and Molecular Pharmacology
University of California, San Francisco
Pamela Silver
Professor of Systems Biology
Harvard Medical School
This project is sponsored by the Alfred P. Sloan Foundation.
Committee on Science, Technology, and Law